Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

National Institute on Drug Abuse (NIDA)582 enrolled

Overview

The purpose of this study is the safety and efficacy of Buprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.

The objective of this study is to provide follow-up compassionate use treatment and evaluate long term safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment for subjects who have completed Cooperative Study 1008 A and B.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

582

Conditions

Opioid Dependence Substance-Related Disorders

Interventions

Buprenorphine/naloxoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 59 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Completion of Cooperative Study 1008 A/B Exclusion Criteria: \- Significant medical or psychiatric illness. Non-compliance with study procedures in the Cooperative Study 1008 A/B

Locations (5)

University of California

Los Angeles, California, United States

VA Medical Center

Tampa, Florida, United States

VA Medical Center

Hines, Illinois, United States

New York VAMC

New York, New York, United States

Outcomes

Primary Outcomes

Craving

Retention

Opioid withdrawal

Subjective rating

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.